Exploring the Landscape of Optic Neuropathy and Vasculopathy: the LOVE study
- Conditions
- Optic neuropathy in individuals with diabetesEye Diseases
- Registration Number
- ISRCTN99411112
- Lead Sponsor
- ational Sun Yat-sen University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 1200
1. Community-registered patients with diabetes
2. Individuals who live in Guangzhou for more than 6 months
3. Aged 18 years and older
4. Individuals who are capable of cooperating with ocular examinations and meeting quality standards
5. Individuals who voluntarily participate in this study
6. Individuals who do not participate in other trials or treatments aimed at preventing or delaying the onset and progression of diabetic retinopathy (DR)
7. Absence of retinal lesions, or retinal/macular lesions not meeting the positive criteria for referable DR
1. Individuals who cannot cooperate with examinations
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ongitudinal change of peripapillary retinal nerve fiber layer thickness measured using optical coherence tomography (OCT) in eligible participants at baseline and each follow-up visit (2 and 4 years)
- Secondary Outcome Measures
Name Time Method 1. Longitudinal change of macular ganglion cell-inner plexiform layer (GCIPL) thickness measured using optical coherence tomography (OCT) in eligible participants at baseline and each follow-up visit (2 and 4 years)<br>2. Longitudinal change of macular ganglion cell complex (GCC) thickness measured using OCT in eligible participants at baseline and each follow-up visit (2 and 4 years)<br>3. Longitudinal change of macular microcirculation measured using optical coherence tomography angiography (OCTA) in eligible participants at baseline and each follow-up visit (2 and 4 years)<br>4. Longitudinal change of microcirculation in optic nerve head measured using OCTA in eligible participants at baseline and each follow-up visit (2 and 4 years)